InvestorsHub Logo

skitahoe

12/11/22 4:41 PM

#547509 RE: Magrit #547502

Magrit, while I agree wholeheartedly that LP has done an amazing job getting us to where we are. I do believe that a BO won't proceed approvals and in fact if we are bought out it won't come before partnerships drive the share price dramatically higher than it goes on regulatory approvals alone.

Personally I'd sure like to know more about DCVax-Direct before a buyout, if it's as good as some believe it may be you can add one zero after the highest price anyone has mentioned for a buyout. I believe if DCVax-Direct works in inoperable cancers it will also be used prior to surgery in operable cancers. My thinking is that if you get something into the cancer before operating that fights the cancer it will get into all the mets. When you surgically remove the cancer it's the mets that are left behind that may grow into cancers years later. If you can pretreat the cancer hopefully you're treating the mets, remove the cancer and hopefully you'll get a cure.

I don't know that I'm right about this, trials take so long that I probably won't be around by the time it's known, but I know it's a fact that mets from the original cancer often take many years to appear, in my sisters case it was roughly a decade. It's been roughly 30 years since my wife's breast cancer, she's had no problem, but after surgery she had heavy chemo and radiation, why? Because they couldn't be certain that mets were all removed so chemo and radiation was recommended. Friends who choose not to take the radiation and chemo after surgery did have cancer reoccur. Wouldn't it be great if DCVax-Direct prior to surgery eliminated the need for chemo and radiation after it.

Gary
Bullish
Bullish

PPHMVERYLONG

12/11/22 5:43 PM

#547531 RE: Magrit #547502

We have no knowledge of a potential buyout and regulatory approval is highly questionable.
If it is not questionable, where is the PR designation from the FDA? What investors want is not the same old "going it alone" strategy that they have practiced for decades to the detriment of the long-suffering shareholders.